Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Uncovering Unmet Needs in Relapsed/Refractory ALL Care

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    From a relatively poor prognosis to severe toxicity risks, patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and the clinicians caring for them face several treatment challenges. Joining Dr. Charles Turck to discuss those unmet needs—and perhaps even more importantly, how we can address them through expert guidance and emerging therapies—is Dr. Ryan Cassaday, Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    From a relatively poor prognosis to severe toxicity risks, patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and the clinicians caring for them face several treatment challenges. Joining Dr. Charles Turck to discuss those unmet needs—and perhaps even more importantly, how we can address them through expert guidance and emerging therapies—is Dr. Ryan Cassaday, Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.

Schedule6 Nov 2024